Chen Weiwei, Qian Wenqi, Nie Jun, Dai Mintao
Department of Gastroenterology, The First People's Hospital of Zunyi (The Third Affiliated Hospital of Zunyi Medical University), Zunyi, People's Republic of China.
Department of Pharmacy, People's Hospital of Qiandongnan and Dong Autonomous Prefecture, Kaili, People's Republic of China.
Clin Exp Med. 2023 Feb;23(1):65-78. doi: 10.1007/s10238-021-00789-7. Epub 2022 Feb 1.
Several malignant solid tumors have been reported to have an abnormal expression of the long non-coding RNA CASC15 (lncRNA CASC15). However, the clinicopathologic and prognostic importance of CASC15 in solid tumors are unknown. As a result, we examined the interrelationship between CASC15, overall survival length, and clinicopathological attributes of cancers affecting humans by analyzing various studies and The Cancer Genome Atlas (TCGA) data related to CASC15 expression.
Web of Science, PubMed, Cochrane Library, Embase, Chinese WanFang, and Chinese CNKI databases were used to conduct a literature search. Hazard ratios (HRs) and Pooled odds ratios (ORs) were calculated taking 95% confidence intervals (CIs). The results of the current meta-analysis were further validated using TCGA datasets.
A total of 12 eligible studies enrolling 767 patients were included in this meta-analysis. Findings of the analysis showed that CASC15 expression had a significant relation to the metastasis of lymph node (OR = 3.30, 95%CI = 1.88-5.81, p < 0.001), distant metastasis (OR = 2.64, 95%CI = 1.24-5.63, p = 0.012), and high TNM/clinical stage (OR = 2.67, 95%CI = 1.34-5.32, p = 0.005). Additionally, we found that a poor outcome for overall survival (OS) was predicted by an elevation in CASC15 expression (HR = 2.01, 95%CI = 1.71-2.36, p < 0.001). Further investigation of the TCGA dataset revealed that CASC15 had abnormal expression in many cancers, which at least partially validated the findings of the current meta-analysis.
According to the latest meta-analysis and systematic review, high expression levels of CASC15 are associated with poor survival outcomes for solid tumor patients, and the use of CASC15 as a solid tumor prognostic predictor has a solid theoretical foundation.
据报道，几种恶性实体瘤中长链非编码RNA CASC15（lncRNA CASC15）存在异常表达。然而，CASC15在实体瘤中的临床病理及预后意义尚不清楚。因此，我们通过分析各项研究以及与CASC15表达相关的癌症基因组图谱（TCGA）数据，研究了CASC15、总生存长度和人类癌症临床病理特征之间的相互关系。
使用科学网、PubMed、Cochrane图书馆、Embase、中国万方和中国知网数据库进行文献检索。计算风险比（HRs）和合并比值比（ORs），并给出95%置信区间（CIs）。使用TCGA数据集进一步验证当前荟萃分析的结果。
本荟萃分析共纳入12项符合条件的研究，涉及767例患者。分析结果显示，CASC15表达与淋巴结转移（OR = 3.30，95%CI = 1.88 - 5.81，p < 0.001）、远处转移（OR = 2.64，95%CI = 1.24 - 5.63，p = 0.012）以及高TNM/临床分期（OR = 2.67，95%CI = 1.34 - 5.32，p = 0.005）显著相关。此外，我们发现CASC15表达升高预示着总生存期（OS）较差（HR = 2.01，95%CI = 1.71 - 2.36，p < 0.001）。对TCGA数据集的进一步研究表明，CASC15在许多癌症中存在异常表达，这至少部分验证了当前荟萃分析的结果。
根据最新的荟萃分析和系统评价，CASC15高表达与实体瘤患者的不良生存结局相关，将CASC15用作实体瘤预后预测指标具有坚实的理论基础。
